Sage Therapeutics Inc

+3.51 (+5.22%)
4:05:04 PM EDT: $70.36 -0.40 (-0.57%)
Regulatory, Earnings Announcements

Sage Therapeutics Reports Positive Interim, Topline Zuranolone Safety And Tolerability Data

Published: 10/15/2020 10:43 GMT
SAGE Therapeutics Inc (SAGE) - Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data From Open-label Shoreline Study in Patients With Mdd.
Sage Therapeutics Inc - Zuranolone Was Generally Well-tolerated at 30 Mg Dose and by Initial Patients Treated With 50 Mg Dose.
Sage Therapeutics Inc - Adverse Event Profile of Zuranolone Consistent With That Seen in Earlier Trials.
Sage Therapeutics Inc - Nearly Half of Trial Participants on Zuranolone 30 Mg Did Not Need an Additional Zuranolone Treatment Course.
Sage Therapeutics Inc - Plans to Report Comprehensive Data From Zuranolone 30 Mg Dose in First Half of 2021.
Sage Therapeutics - Patients Needing Retreatment With 30 Mg Dose, Safety, Tolerability and Efficacy Results Were Similar to Initial Treatment Course.
Revenue is expected to be $1.84 Million
Adjusted EPS is expected to be -$2.30

Next Quarter Revenue Guidance is expected to be $2.82 Million
Next Quarter EPS Guidance is expected to be -$2.47

More details on our Analysts Page.